» Articles » PMID: 16995407

Effective Protection Against Experimental Taenia Solium Tapeworm Infection in Hamsters by Primo-infection and by Vaccination with Recombinant or Synthetic Heterologous Antigens

Overview
Journal J Parasitol
Specialty Parasitology
Date 2006 Sep 26
PMID 16995407
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The disease caused by Taenia solium is progressively being recognized as a growing global threat for public human health and pig husbandry that requires the development of effective control measures. A central participant in the taeniasis/cysticercosis transmission network is the human carrier of the adult tapeworm because of its great potential in spreading the infection. Herein, evidence is presented that a primary infection of golden hamsters with orally administered T. solium cysticerci improved the host's resistance against a secondary infection. Likewise, previous vaccination increased the hamster's resistance. Similar high levels of protection (> 78%) were induced by systemic or oral vaccination with the S3Pvac anticysticercosis synthetic peptide vaccine or the highly immunogenic recombinant chimera based on the protective peptide KETc1 bound to Brucella spp. lumazine synthase (BLS-KETc1). Increased resistance after primo-infection and vaccination possibly results from changes in the immune conditions prevailing in the host's intestine. The contribution to protection from the KETc1 and BLS epitopes in a chimeric vaccine is under study. Preventive vaccination of definitive hosts of T. solium against the tapeworm, the most relevant step in the taeniasis/cysticercosis transmission, may greatly impact the dynamics of endemic disease and has not been studied or tried previously.

Citing Articles

Tamoxifen treatment in hamsters induces protection during taeniosis by Taenia solium.

Escobedo G, Palacios-Arreola M, Olivos A, Lopez-Griego L, Morales-Montor J Biomed Res Int. 2013; 2013:280496.

PMID: 23509701 PMC: 3591190. DOI: 10.1155/2013/280496.


Progesterone induces mucosal immunity in a rodent model of human taeniosis by Taenia solium.

Escobedo G, Camacho-Arroyo I, Nava-Luna P, Olivos A, Perez-Torres A, Leon-Cabrera S Int J Biol Sci. 2011; 7(9):1443-56.

PMID: 22110394 PMC: 3221950. DOI: 10.7150/ijbs.7.1443.


Characterization of S3Pvac anti-cysticercosis vaccine components: implications for the development of an anti-cestodiasis vaccine.

Rassy D, Bobes R, Rosas G, Anaya V, Brehm K, Hernandez B PLoS One. 2010; 5(6):e11287.

PMID: 20585656 PMC: 2890579. DOI: 10.1371/journal.pone.0011287.


Transcriptome analysis of Taenia solium cysticerci using Open Reading Frame ESTs (ORESTES).

Almeida C, Stoco P, Wagner G, Sincero T, Rotava G, Bayer-Santos E Parasit Vectors. 2009; 2(1):35.

PMID: 19646239 PMC: 2731055. DOI: 10.1186/1756-3305-2-35.


Protection against Asiatic Taenia solium induced by a recombinant 45W-4B protein.

Luo X, Zheng Y, Hou J, Zhang S, Cai X Clin Vaccine Immunol. 2008; 16(2):230-2.

PMID: 19091992 PMC: 2643551. DOI: 10.1128/CVI.00367-08.